Physician profile
Delia Deleon
NPI 1205062726
$12,658.70
in general payments reported to CMS, 2019-2025
27 companies · $9,277 in 2025
The $9,277 reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $299 · 2021: $195 · 2022: $1,570 · 2023: $449 · 2024: $372 · 2025: $9,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,000 · Food and Beverage: $1,084 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,000.00 |
| Food and Beverage | $1,084.39 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $9,000.00 | 2025 | Renograft, Ardeograft, Surgraft |
| Therapeuticsmd, INC. | $1,504.26 | 2019-2022 | |
| Abbvie INC. | $442.75 | 2019-2023 | Liletta |
| Mayne Pharma Commercial LLC | $264.78 | 2023-2025 | |
| Hologic Sales and Service, LLC | $228.11 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Thinprep 2000 Processor |
| Exeltis, USA INC. | $147.16 | 2023-2025 | Slynd |
| Biogen, INC. | $119.21 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $96.40 | 2020-2024 | Sos |
| Astellas Pharma US INC | $95.90 | 2023-2024 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $79.75 | 2021-2024 | Phexxi |
| Organon LLC | $77.15 | 2022-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $71.99 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $68.29 | 2019-2020 | |
| Agile Therapeutics, INC. | $66.84 | 2021-2022 | |
| Innovation Technologies INC | $58.25 | 2024 | Irrisept |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $55.45 | 2023-2024 | Intrarosa, Femring |
| Duchesnay USA Incorporated | $51.65 | 2019 | |
| Myovant Sciences INC. | $42.04 | 2021 | |
| Avion Pharmaceuticals | $32.10 | 2020-2021 | |
| Allergan, INC. | $24.87 | 2019 | |
| Lupin INC. | $23.82 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.92 | 2019 | |
| Shield Therapeutics INC | $19.00 | 2022 | |
| Roche Diagnostics Corporation | $18.94 | 2019 | |
| Merck Sharp & Dohme LLC | $17.56 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.52 | 2019 | |
| Davol INC. | $14.99 | 2023 | Arista Ah Flexitip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delia Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.